Merck Nixes Prostate Cancer Study as Keytruda Therapy Disappoints

March 01, 2023

The setbacks were likely to put Merck further behind in its quest to develop a treatment for advanced forms of the most common cancer type in the United States. The decision did not come as a surprise as prostate cancers have historically not been responsive to this class of drugs, said Mara Goldstein, analyst at Mizuho Securities.An interim analysis showed the combination therapy did not extend survival or help extend the time a patient lives without the disease worsening compared to placebo, Merck said.

Better than the past “ file drawer” and cherry-picking of data.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Merck scraps third prostate cancer study as Keytruda therapy disappointsMerck & Co on Tuesday scrapped a late-stage trial of a combination therapy with its cancer drug Keytruda as interim data showed it was unlikely to meet the main goals, making it the drugmaker's third trial for the disease to be abandoned. I’m on it for Kidney cancer and it’s working so far.
Source: Reuters - 🏆 2. / 97 Read more »